U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07213323) titled 'Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment' on Sept. 18.
Brief Summary: Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists (GLP1 RAs) are considered revolutionary in obesity treatment, with three approved molecules available in France: liraglutide, semaglutide, and tirzepatide. These treatments, combined with a healthy lifestyle, induce significant weight loss: 9% with liraglutide, 15% with semaglutide, and 20% with tirzepatide.
The most c...